These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 15761376)
41. Current and future approaches for the therapeutic targeting of metastasis (review). Germanov E; Berman JN; Guernsey DL Int J Mol Med; 2006 Dec; 18(6):1025-36. PubMed ID: 17089005 [TBL] [Abstract][Full Text] [Related]
42. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome. Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647 [TBL] [Abstract][Full Text] [Related]
43. Targets for cancer therapy in childhood sarcomas. Wachtel M; Schäfer BW Cancer Treat Rev; 2010 Jun; 36(4):318-27. PubMed ID: 20223596 [TBL] [Abstract][Full Text] [Related]
44. Peptides with anticancer use or potential. Janin YL Amino Acids; 2003 Jul; 25(1):1-40. PubMed ID: 12836056 [TBL] [Abstract][Full Text] [Related]
45. How to kill cancer cells: membranes and cell signaling as targets in cancer chemotherapy. Tritton TR; Hickman JA Cancer Cells; 1990 Apr; 2(4):95-105. PubMed ID: 2167715 [TBL] [Abstract][Full Text] [Related]
46. Developing new anti-cancer drugs: novel targets and methodological problems. Spataro V; Sessa C Forum (Genova); 1999; 9(3):200-9. PubMed ID: 10504168 [TBL] [Abstract][Full Text] [Related]
47. New targets for cancer chemotherapy. Murgo AJ; Dancey J; Eckhardt SG; Hidalgo M; Arbuck SG; Zerivitz K; Blaylock BA Cancer Chemother Biol Response Modif; 2002; 20():239-72. PubMed ID: 12703208 [No Abstract] [Full Text] [Related]
49. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1. Henkin J; Volpert OV Expert Opin Ther Targets; 2011 Dec; 15(12):1369-86. PubMed ID: 22136063 [TBL] [Abstract][Full Text] [Related]
50. Medicinal mushroom modulators of molecular targets as cancer therapeutics. Zaidman BZ; Yassin M; Mahajna J; Wasser SP Appl Microbiol Biotechnol; 2005 Jun; 67(4):453-68. PubMed ID: 15726350 [TBL] [Abstract][Full Text] [Related]
51. [Impact of oncologic therapeutic concepts 2004]. Zielinski CC Acta Med Austriaca; 2004; 31(4):139-43. PubMed ID: 15732250 [TBL] [Abstract][Full Text] [Related]
52. Killing time for cancer cells. Klein S; McCormick F; Levitzki A Nat Rev Cancer; 2005 Jul; 5(7):573-80. PubMed ID: 15965492 [TBL] [Abstract][Full Text] [Related]
53. Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Kabore AF; Johnston JB; Gibson SB Curr Cancer Drug Targets; 2004 Mar; 4(2):147-63. PubMed ID: 15032666 [TBL] [Abstract][Full Text] [Related]
54. Recent developments in peptide-based cancer therapeutics. Sehgal A Curr Opin Drug Discov Devel; 2002 Mar; 5(2):245-50. PubMed ID: 11926130 [TBL] [Abstract][Full Text] [Related]
55. Exploring Proteomic Drug Targets, Therapeutic Strategies and Protein - Protein Interactions in Cancer: Mechanistic View. Dar KB; Bhat AH; Amin S; Anjum S; Reshi BA; Zargar MA; Masood A; Ganie SA Curr Cancer Drug Targets; 2019; 19(6):430-448. PubMed ID: 30073927 [TBL] [Abstract][Full Text] [Related]
56. Molecularly targeted therapies for glioma. Yamanaka R; Saya H Ann Neurol; 2009 Dec; 66(6):717-29. PubMed ID: 20035507 [TBL] [Abstract][Full Text] [Related]
57. Pro-apoptotic peptides-based cancer therapies: challenges and strategies to enhance therapeutic efficacy. Min KA; Maharjan P; Ham S; Shin MC Arch Pharm Res; 2018 Jun; 41(6):594-616. PubMed ID: 29804279 [TBL] [Abstract][Full Text] [Related]
58. Recent advances in anticancer drugs. Niculescu Duvaz I IDrugs; 1998 Aug; 1(4):408-11. PubMed ID: 18465571 [TBL] [Abstract][Full Text] [Related]